Alcon will expand its femtosecond laser-assisted cataract surgery offerings with a deal to acquire Lensar, according to a press release.
Alcon will buy all of Lensar’s outstanding shares for $14 per share in cash. It will also offer an additional $2.75 per share with the condition that more than 614,000 cumulative procedures are performed with Lensar’s products between Jan. 1, 2026, and Dec. 31, 2027, giving the acquisition a potential value of about $430 million, according to the release.
The deal includes the Ally robotic cataract laser treatment system, (Read more...)